T0	Participants 35 106	previously treated, PD-L1-positive, advanced non-small-cell lung cancer
T1	Participants 209 244	advanced non-small-cell lung cancer
T2	Participants 377 449	previously treated, PD-L1-positive, advanced non-small-cell lung cancer.
T3	Participants 513 558	202 academic medical centres in 24 countries.
T4	Participants 559 671	Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells
T5	Participants 1279 1345	Between Aug 28, 2013, and Feb 27, 2015, we enrolled 1034 patients:
T6	Participants 3177 3263	patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.